Rosuvastatin

Drug Profile

Rosuvastatin

Alternative Names: Crestor; CRESTOR OD; Rosuvas; Rosuvastatin calcium; S 4522; ZD 4522

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Shionogi
  • Developer AstraZeneca; Shionogi
  • Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
  • Discontinued Heart failure

Most Recent Events

  • 30 Nov 2016 AstraZeneca completes the extension study of the phase III HYDRA trial for Hypercholesterolaemia (In adolescents, In children) in Belgium, Canada, Denmark, Israel, Malaysia and Taiwan (NCT02434497)
  • 27 Aug 2016 Pooled efficacy and adverse events data from the phase III HYDRA and CHARON trials in Hypercholesterolaemia (In children, In adolescents) released by AstraZeneca
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top